Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 10,000 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 10,000 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the sale, the chief executive officer now owns 1,292,987 shares of the company’s stock, valued at $38,983,558.05. This trade represents a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, February 5th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $40.58, for a total transaction of $608,700.00.
• On Wednesday, January 8th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.85, for a total transaction of $732,750.00.

Apogee Therapeutics Price Performance

APGE opened at $36.14 on Friday. Apogee Therapeutics, Inc. has a one year low of $29.10 and a one year high of $72.29. The company’s 50 day simple moving average is $39.12 and its 200-day simple moving average is $47.02. The stock has a market capitalization of $1.63 billion, a P/E ratio of -14.93 and a beta of 2.46.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.25). As a group, analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on APGE. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Wedbush reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Apogee Therapeutics in a report on Monday, March 3rd. Finally, Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $91.60.

Hedge Funds Weigh In On Apogee Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Apogee Therapeutics during the fourth quarter worth $6,521,000. GF Fund Management CO. LTD. bought a new position in shares of Apogee Therapeutics during the fourth quarter worth $43,000. Neo Ivy Capital Management bought a new position in shares of Apogee Therapeutics during the fourth quarter worth $1,745,000. Woodline Partners LP boosted its position in shares of Apogee Therapeutics by 4.0% during the fourth quarter. Woodline Partners LP now owns 1,015,608 shares of the company’s stock worth $46,007,000 after purchasing an additional 39,453 shares in the last quarter. Finally, Soleus Capital Management L.P. bought a new position in shares of Apogee Therapeutics during the fourth quarter worth $3,171,000. 79.04% of the stock is owned by institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.